查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1377407

口干症治疗市场 - 全球产业规模、份额、趋势、机会和预测，2018-2028 按类型、产品、地区、竞争预测和机会细分，2018-2028F

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Product, By Region, By Competition Forecast & Opportunities, 2018-2028F
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球口干症治疗市场价值为 19.8 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年复合CAGR为3.69%。由于化疗和治疗的日益普及，预计该市场成长将显着推动。用于癌症治疗的放射疗法，以及处方药物的使用不断增加。口干症的特征是唾液分泌减少导致口腔干燥，可导致口干、口腔灼热感、吞嚥困难以及味觉减退或丧失。化学治疗和放射治疗会损害唾液腺，导致口干。化疗是肿瘤学家和医生提供的最常见的癌症治疗方法，通常会导致口干症的副作用。此外，口干症也可能由药物、头颈部放射治疗、化疗甚至干燥症引起。截至 2016 年 1 月 1 日，美国癌症协会报告称，美国有 350 万名女性患有乳癌。在患有 IV 期乳癌的女性中，48% 接受放射治疗和/或化学治疗作为治疗的一部分。

主要市场驱动因素

导致口干症的发生率不断增加

市场概况
预测期 2024-2028
2022 年市场规模 19.8亿美元
2028 年市场规模 24.4亿美元
2023-2028 年CAGR 3.69%
成长最快的细分市场 场外交易
最大的市场 北美洲

口干症通常称为口干，是一种以唾液流量减少为特征的常见病症。虽然口干症看起来似乎是一个小小的不便，但它会对个人的生活品质产生重大影响，影响他们说话、吃饭甚至享受食物的能力。全球口干症治疗市场正在经历显着成长，而这种扩张背后的关键驱动因素之一是导致口干症的发病率不断增加。癌症是导致口干症发生率增加的主要原因。化学治疗和放射治疗是两种常见的癌症治疗方法，通常会导致唾液腺受损，导致口干。随着全球癌症负担持续上升，因这些治疗的副作用而出现口干症的患者数量也在增加。这创造了大量寻求缓解口干的患者群体，从而推动了对口干症治疗的需求。世界人口正在老化，老年人口的比例比以往任何时候都高。随着年龄的增长，他们往往会出现多种需要药物治疗的健康问题。许多这些药物都有口干的副作用。随着老年人服用更多药物，该族群口干的盛行率正在上升。这种人口结构的变化极大地促进了口干症治疗市场的成长。多重用药，即一个人同时使用多种药物，正变得越来越普遍。患有慢性疾病的人经常服用多种药物来控制疾病，这可能会增加口干症副作用的可能性。这种现象增加了对口干症治疗的需求，因为越来越多的患者需要有效的解决方案来缓解口干症状。干燥症（一种主要影响唾液腺和泪腺的自体免疫疾病）等疾病可能会导致慢性口干。自体免疫疾病的盛行率正在上升，这对患有口干症的人数有直接影响。随着人们对这些疾病的认识不断增强，越来越多的患者被诊断出来，对口干症治疗的需求不断增加。医疗保健专业人员越来越擅长诊断口干症并认识到它是一个重要的健康问题。这种改进的诊断和报告导致更多的患者寻求针对口干症状的治疗，进一步推动了口干症治疗市场的发展。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球口干症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液兴奋剂、唾液替代品、洁齿剂）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 按类型
    • 按产品分类
    • 按地区

第 6 章：北美口干症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液兴奋剂、唾液替代品、洁齿剂）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲口干症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液兴奋剂、唾液替代品、洁齿剂）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区口干症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液兴奋剂、唾液替代品、洁齿剂）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲口干症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液兴奋剂、唾液替代品、洁齿剂）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲口干症治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（非处方药、处方药）
    • 副产品（唾液兴奋剂、唾液替代品、洁齿剂）
    • 按国家/地区
  • MEA：国家分析
    • 南非口干症治疗公司
    • 沙乌地阿拉伯 口干症治疗
    • 阿联酋口干症治疗公司
    • 科威特口干症治疗

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • Acacia Pharma Ltd
    • Parnell Pharmaceuticals Holdings Ltd
    • Pfizer Inc
    • GSK PLC
    • Church & Dwight Co Inc
    • Lupin Pharmaceuticals Inc
    • Sun Pharmaceutical Industries Ltd
    • Hikma Pharmaceuticals PLC.
    • Pendopharm Inc
    • OraCoat

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 16619

Global Xerostomia Therapeutics Market has valued at USD 1.98 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 3.69% through 2028. The market growth is expected to receive a significant boost due to the increasing adoption of chemotherapy and radiotherapy for cancer treatment, along with the rising use of prescribed medications. Xerostomia, characterized by oral dryness resulting from reduced saliva production, can lead to sensations of mouth dryness, oral burning, difficulty in swallowing, and a decrease or loss of taste. The salivary glands are damaged by chemotherapy and radiation therapy, resulting in dry mouth. Chemotherapy, the most common cancer treatment provided by oncologists and medical practitioners, often leads to xerostomia as a side effect. Additionally, xerostomia can be caused by medication, head and neck radiation therapy, chemotherapy, and even Sjogren's syndrome. As of January 1, 2016, the American Cancer Society reported that 3.5 million women in the U.S. were living with breast cancer. Among women with stage IV breast cancer, 48% received radiation and/or chemotherapy as part of their treatment.

Key Market Drivers

Increasing Incidence of Xerostomia-Causing Conditions

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.98 Billion
Market Size 2028USD 2.44 Billion
CAGR 2023-20283.69%
Fastest Growing SegmentOTC
Largest MarketNorth America

Xerostomia, commonly known as dry mouth, is a prevalent condition characterized by a reduced flow of saliva. While it may seem like a minor inconvenience, xerostomia can have a significant impact on an individual's quality of life, affecting their ability to speak, eat, and even enjoy food. The global xerostomia therapeutics market is experiencing remarkable growth, and one of the key drivers behind this expansion is the increasing incidence of xerostomia-causing conditions. Cancer is a major contributor to the increasing incidence of xerostomia-causing conditions. Chemotherapy and radiation therapy, two common treatments for cancer, often lead to damage to the salivary glands, resulting in dry mouth. As the global cancer burden continues to rise, the number of patients experiencing xerostomia as a side effect of these treatments is also increasing. This creates a substantial patient pool seeking relief from dry mouth, thus driving the demand for xerostomia therapeutics. The world's population is aging, with a higher proportion of elderly individuals than ever before. As people age, they tend to develop multiple health issues that require medication. Many of these medications have xerostomia as a side effect. With the elderly population taking more medications, the prevalence of dry mouth among this demographic is on the rise. This demographic shift significantly contributes to the growth of the xerostomia therapeutics market. Polypharmacy, the concurrent use of multiple medications by an individual, is becoming increasingly common. People with chronic health conditions often take multiple drugs to manage their ailments, which can increase the likelihood of experiencing xerostomia as a side effect. This phenomenon amplifies the demand for xerostomia therapeutics as more patients require effective solutions to alleviate dry mouth symptoms. Conditions like Sjogren's syndrome, an autoimmune disease that primarily affects the salivary and tear glands, can lead to chronic dry mouth. The prevalence of autoimmune diseases is on the rise, and this has a direct impact on the number of individuals experiencing xerostomia. As awareness of these diseases grows and more patients are diagnosed, the demand for xerostomia therapeutics continues to increase. Healthcare professionals are becoming more adept at diagnosing xerostomia and recognizing it as a significant health concern. This improved diagnosis and reporting have led to more patients seeking treatment for their dry mouth symptoms, further bolstering the xerostomia therapeutics market.

Advances in Xerostomia Therapeutics

Xerostomia, commonly referred to as dry mouth, is a condition characterized by insufficient saliva production, leading to discomfort and potential oral health complications. It affects millions of individuals worldwide and can be caused by various factors, including medication, radiation therapy, and systemic diseases. The global xerostomia therapeutics market is witnessing significant growth, primarily due to continuous advancements in treatment options. One of the most prominent factors contributing to the growth of the xerostomia therapeutics market is the development of innovative medications specifically designed to combat dry mouth. Pharmaceutical companies are investing in research and development to create drugs that stimulate salivary gland function or mimic the properties of saliva. These breakthrough medications offer patients more effective and targeted relief from xerostomia symptoms. Advances in the formulation of saliva substitutes have provided patients with viable alternatives to natural saliva. These substitutes aim to replicate the properties of saliva, such as lubrication and pH balance, to alleviate dry mouth symptoms effectively. As these products become more sophisticated and accessible, they contribute significantly to the growth of the xerostomia therapeutics market. Biotechnology plays a crucial role in the development of xerostomia therapeutics. Researchers are exploring biotechnological approaches to stimulate saliva production and improve the overall oral health of individuals suffering from dry mouths. These innovations offer promising solutions and enhance the market's potential for growth. Advances in healthcare technology enable the customization of xerostomia treatment plans for individual patients. With the availability of personalized therapies, healthcare providers can tailor interventions to the unique needs and preferences of each patient. This tailored approach not only enhances patient satisfaction but also drives demand for xerostomia therapeutics. Drug delivery systems have evolved significantly, making it easier for patients to administer xerostomia therapeutics. Improved formulations, such as oral sprays, gels, and lozenges, offer convenience and more effective delivery of medications or substitutes, further boosting patient compliance and market growth. Advances in patient education and awareness campaigns have led to increased recognition of the importance of managing xerostomia. As more individuals become aware of the available treatment options, they are likely to seek out therapies that provide relief from dry mouth symptoms, driving market expansion.

Growing Awareness and Diagnosis Rates

Xerostomia, more commonly known as dry mouth, is a condition characterized by a reduced production of saliva, which can result in significant discomfort and oral health issues. It is caused by various factors, including medication, radiation therapy, and certain medical conditions. The global xerostomia therapeutics market is on a growth trajectory, largely driven by the increasing awareness of this condition among both patients and healthcare professionals, as well as the improved rates of diagnosis. One of the key factors driving the growth of the xerostomia therapeutics market is the increasing emphasis on patient education. Healthcare organizations, advocacy groups, and pharmaceutical companies are actively engaged in educational campaigns to raise awareness about xerostomia. Patients are now better informed about the condition's symptoms and consequences, which leads to a higher likelihood of seeking medical assistance and treatment. Healthcare professionals, including dentists, oncologists, and primary care physicians, are becoming more proficient in recognizing xerostomia. They are now better equipped to identify the condition's signs during routine examinations and consultations. As a result, patients are being diagnosed more accurately and promptly, leading to an increased demand for xerostomia therapeutics. Xerostomia is often a symptom of underlying health conditions, such as Sjogren's syndrome or diabetes. As awareness of these conditions grows, so does the recognition of xerostomia as a related concern. Patients with these underlying conditions are more likely to be screened for dry mouth, thus contributing to increased diagnosis rates and the demand for appropriate therapeutics. The internet and various media outlets have played a significant role in disseminating information about xerostomia. Patients can easily access information about the condition's causes, symptoms, and available treatments. This ease of access empowers individuals to seek help and inquire about xerostomia therapeutics during medical appointments. The development of improved diagnostic tools and techniques has facilitated the identification of xerostomia. Salivary flow tests, imaging, and other diagnostic methods have become more precise, allowing healthcare providers to diagnose dry mouth more accurately. This, in turn, drives the demand for xerostomia therapeutics.

Research and Development Efforts

Xerostomia, commonly known as dry mouth, is a medical condition characterized by a lack of saliva production in the mouth. This condition can be caused by various factors, including medication side effects, medical treatments, and underlying health conditions. Xerostomia not only affects the comfort and quality of life for those who suffer from it but also poses potential risks to oral health. As the global population ages and the prevalence of xerostomia continues to rise, there is a pressing need for effective therapeutic solutions. Research and development (R&D) efforts play a pivotal role in addressing this need and driving the growth of the global xerostomia therapeutics market. Xerostomia is not merely an inconvenience but a condition that can have far-reaching consequences. Saliva plays a crucial role in maintaining oral health by helping to digest food, neutralizing acids, and preventing tooth decay. The xerostomia therapeutics market is poised for significant growth, primarily due to the aging population and the rising prevalence of conditions such as Sjogren's syndrome, diabetes, and cancer, which are known to cause dry mouth. R&D endeavors can lead to the development of innovative therapies tailored to address the specific causes and symptoms of xerostomia. These may include pharmaceuticals, biologics, and advanced oral care products. Research can help identify biomarkers and genetic factors that contribute to xerostomia. This knowledge can pave the way for personalized treatment approaches, ensuring better outcomes for patients. R&D allows for rigorous clinical trials and studies that evaluate the safety and efficacy of xerostomia therapies. This data is vital for gaining regulatory approvals and building trust among healthcare providers and patients. R&D efforts can also contribute to increased awareness and education about xerostomia among both healthcare professionals and the general public, leading to earlier diagnosis and treatment. As new and improved xerostomia therapies emerge, the global market for these treatments is expected to expand significantly. This growth not only benefits pharmaceutical companies but also creates opportunities for healthcare professionals and patients alike. To harness the full potential of R&D in boosting the xerostomia therapeutics market, collaboration between pharmaceutical companies, research institutions, healthcare providers, and patient advocacy groups is essential. This synergy can expedite the development of promising therapies and ensure they reach the market sooner. Investment in R&D is equally crucial. Governments, private investors, and philanthropic organizations can play a pivotal role in funding research initiatives focused on xerostomia. These investments can help accelerate breakthroughs and reduce the time it takes for new treatments to become available to those in need.

Key Market Challenges

Limited Understanding of Xerostomia Causes

One of the primary challenges in the xerostomia therapeutics market is the limited understanding of the diverse causes of dry mouth. While some cases are medication-induced, others result from medical treatments or underlying health conditions. Identifying the exact cause of xerostomia in each patient is essential for tailoring effective treatments. The lack of comprehensive knowledge can lead to misdiagnoses and ineffective therapies.

Complexity of Treatment Approaches

Xerostomia is a multifaceted condition with numerous contributing factors. Developing effective treatments that address these complexities is challenging. Traditional approaches often focus on symptomatic relief, such as saliva substitutes or stimulants. However, addressing the root causes of xerostomia, such as salivary gland dysfunction or autoimmune diseases like Sjogren's syndrome, requires innovative and personalized therapies. These approaches can be expensive and time-consuming to develop.

Patient Compliance and Adherence

Even when effective treatments are available, patient compliance and adherence can be problematic. Xerostomia may be a chronic condition, and patients may need to use therapies consistently for prolonged periods. Overcoming the inconvenience and potential side effects of treatments can be a barrier to patient adherence, reducing treatment efficacy.

Cost of Therapies

Some xerostomia therapeutics, particularly novel and innovative treatments, can be costly. This cost can be a significant burden for patients, particularly when treatments are not covered by insurance or healthcare systems. Access to affordable therapies is crucial for ensuring that xerostomia patients receive the care they need.

Key Market Trends

Personalized Medicine and Biomarker Development

One of the most promising trends in the xerostomia therapeutics market is the move towards personalized medicine. Researchers are actively identifying biomarkers and genetic factors that contribute to xerostomia. This allows for tailoring treatments to individual patients, increasing treatment efficacy, and minimizing side effects. By understanding the unique genetic and physiological aspects of each patient, healthcare providers can prescribe treatments that are more likely to succeed.

Innovative Drug Formulations

Innovations in drug formulation are paving the way for more convenient and effective xerostomia treatments. Recent developments include novel drug delivery systems such as mouth sprays, gels, and mucoadhesive patches. These formulations aim to provide longer-lasting relief, enhance patient compliance, and improve the overall treatment experience.

Digital Health Solutions

The integration of digital health solutions is transforming the way xerostomia is managed. Mobile apps, wearable devices, and telehealth platforms are being developed to help patients monitor their oral health, track medication adherence, and receive real-time guidance from healthcare professionals. These digital tools not only empower patients but also enable remote monitoring and data-driven treatment adjustments.

Natural and Herbal Remedies

Consumer interest in natural and herbal remedies is influencing the xerostomia therapeutics market. Several herbal products and natural supplements are gaining popularity for their potential to alleviate dry mouth symptoms. Research is ongoing to validate the safety and efficacy of these remedies, which could provide alternative options for patients seeking holistic approaches to managing xerostomia.

Segmental Insights

Type Insights

Based on the category of Type, the market can be divided into two segments: Over-the-Counter (OTC) and prescription. In 2022, the OTC segment held the largest market share, and it is anticipated to exhibit significant growth at a favorable compound annual growth rate (CAGR) throughout the projected period. This dominance can be attributed to several factors, including the wide range of available products, their safety and effectiveness, the presence of limited branded drugs, and competitive pricing.

OTC products represent the primary approach for addressing xerostomia, and for most cases of xerostomia, these products are sufficient and pose no complications. In instances of severe xerostomia, prescription medications may be necessary. Through proper care and medication, xerostomia can be effectively managed and controlled, thereby preventing any potential complications.

Product Insights

The market can be segmented based on product into salivary stimulants, salivary substitutes, and dentifrices. In 2022, the salivary stimulants segment was the market leader. Salivary stimulants are substances designed to enhance the production of saliva and can be further categorized as pharmacological (affecting the nervous system) or non-pharmacological (influencing taste buds or chewing muscles). They come in various forms, including mints, sugar-free chewing gums, sprays, and lozenges. In November 2018, 3M introduced the Xerostomia Relief Spray, which provides relief for up to 4 hours by moistening and lubricating mucosa. In September 2021, ICPA Health Products Ltd. launched Wet Mouth, a saliva substitute based on sodium carboxymethyl cellulose, designed to treat xerostomia and reduce surface abrasion.

The dentifrices segment is projected to experience the most rapid growth in terms of CAGR during the forecast period. Dentifrices are specialized dental cleaning agents, powders, or pastes that help alleviate dry mouth by eliminating irritants that contribute to dryness. GC America Inc.'s MI Paste and MI Paste Plus are products that can be applied to the teeth to stimulate saliva production and restore essential saliva components such as calcium and phosphate.

Regional Insights

In 2022, the North American region emerged as the dominant player in the market. The primary factors contributing to this dominance include the growing prevalence of conditions like xerostomia and related ailments such as Sjogren's syndrome and rheumatoid arthritis. Additionally, the increasing awareness campaigns focused on dry mouth have played a pivotal role in this dominance. Notably, the Sjogren's Foundation's "April is Sjogren's Awareness Month" campaign has significantly contributed to raising awareness about Sjogren's syndrome.

Looking ahead, the Asia Pacific region is expected to exhibit the most rapid CAGR during the forecast period. This growth can be attributed to several key factors, including the escalation in healthcare expenditure, heightened awareness campaigns, and a rising incidence of conditions like diabetes, cancer, and Parkinson's disease. According to a study conducted by the National Institutes of Health (NIH), between 1990 and 2019, the occurrences of Parkinson's disease witnessed substantial increases in East Asia, South Asia, Southeast Asia, and Central Asia, with growth rates of 202.22%, 204.06%, 164.21%, and 67.93%, respectively.

Key Market Players

Acacia Pharma Ltd

Parnell Pharmaceuticals Holdings Ltd

Pfizer Inc

GSK PLC

Church & Dwight Co Inc

Lupin Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd

Hikma Pharmaceuticals PLC.

Pendopharm Inc

OraCoat

Report Scope:

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type:

  • OTC
  • Prescription

Xerostomia Therapeutics Market, By Product:

  • Salivary Stimulants
  • Salivary Substitutes
  • Dentifrices

Xerostomia Therapeutics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

  • Global Xerostomia Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xerostomia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (OTC, Prescription)
    • 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Type
    • 5.3.2. By Product
    • 5.3.3. By Region

6. North America Xerostomia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (OTC, Prescription)
    • 6.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Xerostomia Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Xerostomia Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (OTC, Prescription)
    • 7.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Xerostomia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
    • 7.3.2. United Kingdom Xerostomia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
    • 7.3.3. France Xerostomia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Xerostomia Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Xerostomia Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product

8. Asia-Pacific Xerostomia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (OTC, Prescription)
    • 8.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Xerostomia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
    • 8.3.2. Japan Xerostomia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
    • 8.3.3. India Xerostomia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
    • 8.3.4. Australia Xerostomia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
    • 8.3.5. South Korea Xerostomia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product

9. South America Xerostomia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (OTC, Prescription)
    • 9.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Xerostomia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
    • 9.3.2. Argentina Xerostomia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
    • 9.3.3. Colombia Xerostomia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product

10. Middle East and Africa Xerostomia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (OTC, Prescription)
    • 10.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Xerostomia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
    • 10.3.2. Saudi Arabia Xerostomia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
    • 10.3.3. UAE Xerostomia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
    • 10.3.4. Kuwait Xerostomia Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Acacia Pharma Ltd
    • 14.6.2. Parnell Pharmaceuticals Holdings Ltd
    • 14.6.3. Pfizer Inc
    • 14.6.4. GSK PLC
    • 14.6.5. Church & Dwight Co Inc
    • 14.6.6. Lupin Pharmaceuticals Inc
    • 14.6.7. Sun Pharmaceutical Industries Ltd
    • 14.6.8. Hikma Pharmaceuticals PLC.
    • 14.6.9. Pendopharm Inc
    • 14.6.10. OraCoat

15. Strategic Recommendations

16. About Us & Disclaimer